GFM
GF Fund Management Portfolio holdings
AUM
$4.97B
This Quarter Return
+7.58%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$4.62B
AUM Growth
–
Cap. Flow
+$4.62B
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
48.03%
Holding
637
New
637
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
NVIDIA
NVDA
|
$390M |
| 2 |
Apple
AAPL
|
$374M |
| 3 |
Microsoft
MSFT
|
$322M |
| 4 |
Amazon
AMZN
|
$234M |
| 5 |
Meta Platforms (Facebook)
META
|
$194M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Technology | 45.53% |
| 2 | Consumer Discretionary | 17.29% |
| 3 | Communication Services | 14.35% |
| 4 | Healthcare | 6.6% |
| 5 | Consumer Staples | 4.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
451
Harrow
HROW
$1.37B
| $25.1K | ﹤0.01% |
+748
| New | +$25.1K |
|
|
VRE
452
Veris Residential
VRE
$1.52B
| $25.1K | ﹤0.01% |
+1,507
| New | +$25.1K |
|
453
Intellia Therapeutics
NTLA
$1.29B
| $24.9K | ﹤0.01% |
+2,139
| New | +$24.9K |
|
454
Immunocore
IMCR
$1.87B
| $24.5K | ﹤0.01% |
+831
| New | +$24.5K |
|
455
ANI Pharmaceuticals
ANIP
$2.07B
| $24.4K | ﹤0.01% |
+441
| New | +$24.4K |
|
|
ELME
456
Elme Communities
ELME
$1.52B
| $24.2K | ﹤0.01% |
+1,587
| New | +$24.2K |
|
457
Rocket Pharmaceuticals
RCKT
$354M
| $24.1K | ﹤0.01% |
+1,914
| New | +$24.1K |
|
458
Syndax Pharmaceuticals
SNDX
$1.47B
| $23.7K | ﹤0.01% |
+1,792
| New | +$23.7K |
|
|
ALEX
459
Alexander & Baldwin
ALEX
$1.41B
| $23.2K | ﹤0.01% |
+1,309
| New | +$23.2K |
|
460
Enliven Therapeutics
ELVN
$1.19B
| $23.1K | ﹤0.01% |
+1,026
| New | +$23.1K |
|
|
AAT
461
American Assets Trust
AAT
$1.26B
| $23.1K | ﹤0.01% |
+879
| New | +$23.1K |
|
462
Innoviva
INVA
$1.29B
| $22.8K | ﹤0.01% |
+1,314
| New | +$22.8K |
|
|
JBGS
463
JBG SMITH
JBGS
$1.4B
| $22.8K | ﹤0.01% |
+1,482
| New | +$22.8K |
|
464
ARS Pharmaceuticals
SPRY
$995M
| $21.5K | ﹤0.01% |
+2,041
| New | +$21.5K |
|
|
AVDL
465
Avadel Pharmaceuticals
AVDL
$1.53B
| $21.3K | ﹤0.01% |
+2,023
| New | +$21.3K |
|
466
Vir Biotechnology
VIR
$732M
| $21.2K | ﹤0.01% |
+2,892
| New | +$21.2K |
|
467
Zymeworks
ZYME
$1.14B
| $21.2K | ﹤0.01% |
+1,446
| New | +$21.2K |
|
|
AIV
468
Aimco
AIV
$1.11B
| $20.9K | ﹤0.01% |
+2,298
| New | +$20.9K |
|
|
PDM
469
Piedmont Realty Trust, Inc.
PDM
$1.09B
| $20.5K | ﹤0.01% |
+2,236
| New | +$20.5K |
|
|
DEA
470
Easterly Government Properties
DEA
$1.05B
| $20.1K | ﹤0.01% |
+706
| New | +$20.1K |
|
|
NTST
471
NETSTREIT Corp
NTST
$1.72B
| $19.7K | ﹤0.01% |
+1,395
| New | +$19.7K |
|
472
Replimune Group
REPL
$494M
| $19.6K | ﹤0.01% |
+1,616
| New | +$19.6K |
|
473
Collegium Pharmaceutical
COLL
$1.21B
| $19.4K | ﹤0.01% |
+677
| New | +$19.4K |
|
474
89bio
ETNB
$1.32B
| $19.3K | ﹤0.01% |
+2,469
| New | +$19.3K |
|
475
Anavex Life Sciences
AVXL
$807M
| $19.1K | ﹤0.01% |
+1,780
| New | +$19.1K |
|